181 related articles for article (PubMed ID: 38228803)
1. FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis.
Ursic-Bedoya J; Desandré G; Chavey C; Marie P; Polizzi A; Rivière B; Guillou H; Assenat E; Hibner U; Gregoire D
EMBO Mol Med; 2024 Feb; 16(2):238-250. PubMed ID: 38228803
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 19 stimulates water intake.
Ursic-Bedoya J; Chavey C; Desandré G; Meunier L; Dupuy AM; Gonzalez-Dopeso Reyes I; Tordjmann T; Assénat E; Hibner U; Gregoire D
Mol Metab; 2022 Jun; 60():101483. PubMed ID: 35367668
[TBL] [Abstract][Full Text] [Related]
3. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
4. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.
Zhou M; Yang H; Learned RM; Tian H; Ling L
Nat Commun; 2017 May; 8():15433. PubMed ID: 28508871
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
[TBL] [Abstract][Full Text] [Related]
6. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
[TBL] [Abstract][Full Text] [Related]
7. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
[TBL] [Abstract][Full Text] [Related]
8. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
10. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
11. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
12. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200
[TBL] [Abstract][Full Text] [Related]
14. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
15. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.
Wang J; Zhao H; Zheng L; Zhou Y; Wu L; Xu Y; Zhang X; Yan G; Sheng H; Xin R; Jiang L; Lei J; Zhang J; Chen Y; Peng J; Chen Q; Yang S; Yu K; Li D; Xie Q; Li Y
Theranostics; 2021; 11(10):5045-5060. PubMed ID: 33754043
[No Abstract] [Full Text] [Related]
16. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.
Sawey ET; Chanrion M; Cai C; Wu G; Zhang J; Zender L; Zhao A; Busuttil RW; Yee H; Stein L; French DM; Finn RS; Lowe SW; Powers S
Cancer Cell; 2011 Mar; 19(3):347-58. PubMed ID: 21397858
[TBL] [Abstract][Full Text] [Related]
17. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G
Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001
[TBL] [Abstract][Full Text] [Related]
18. Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects.
Liu H; Zheng S; Hou X; Liu X; Du K; Lv X; Li Y; Yang F; Li W; Sui J
Cancer Sci; 2020 May; 111(5):1750-1760. PubMed ID: 32061104
[TBL] [Abstract][Full Text] [Related]
19. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
20. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
